<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619004</url>
  </required_header>
  <id_info>
    <org_study_id>U31402-A-U201</org_study_id>
    <secondary_id>2020-000730-17</secondary_id>
    <nct_id>NCT04619004</nct_id>
  </id_info>
  <brief_title>HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer</brief_title>
  <official_title>HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the antitumor activity of patritumab deruxtecan in&#xD;
      participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon&#xD;
      19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1&#xD;
      platinum-based chemotherapy-containing regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will initially randomize participants to one of 2 arms in a 1:1 ratio to receive&#xD;
      either a 5.6 mg/kg fixed dose regimen or an up-titration dose regimen of patritumab&#xD;
      deruxtecan (HER3-DXd, U3-1402).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 26 months</time_frame>
    <description>ORR is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 26 months</time_frame>
    <description>DoR is defined as the time from the first documented confirmed response (CR or PR) to the date of progression or death due to any cause as assessed by BICR and Investigator per RECIST v1.1, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 26 months</time_frame>
    <description>PFS is defined as the time from the start of study treatment to the earlier of the dates of the first documentation of objective progressive disease (PD) per RECIST v1.1 or death due to any cause. PFS will be determined by BICR and by Investigator, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as Assessed by the Investigator</measure>
    <time_frame>Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 26 months</time_frame>
    <description>ORR is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR as assessed by the Investigator per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 26 months</time_frame>
    <description>DCR is defined as the proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) as assessed by BICR and by the Investigator per RECIST v1.1, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 26 months</time_frame>
    <description>TTR is defined as the time from the start of study treatment to the date of the first documentation of confirmed response (CR or PR) as assessed by BICR and Investigator per RECIST v1.1, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best percentage change in the sum of diameters (SoD) of measurable tumors</measure>
    <time_frame>Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 26 months</time_frame>
    <description>The best percentage change in the SoD of measurable tumors is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Death date is collected until the participant discontinues the study or up to approximately 26 months</time_frame>
    <description>OS defined as the time from the start of study treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)</measure>
    <time_frame>From baseline up to Day 47 post last dose</time_frame>
    <description>A TEAE is defined as an adverse event (AE) with a start or worsening date during the on-treatment period. A serious AE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event, or may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes noted. AESIs will also be assessed. Adverse events will be coded using MedDRA and will be graded using NCI-CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Non-Small Cell Lung Cancer Metastatic</condition>
  <condition>Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor</condition>
  <arm_group>
    <arm_group_label>Study Group 1: Patritumab deruxtecan 5.6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Group 1 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan 5.6 mg/kg IV every 3 weeks (Q3W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2: Patritumab deruxtecan Up-Titration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Group 2 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan up-titration IV every 3 weeks (Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patritumab Deruxtecan (Fixed dose)</intervention_name>
    <description>Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Study Group 1: Patritumab deruxtecan 5.6 mg/kg</arm_group_label>
    <other_name>U3-1402</other_name>
    <other_name>HER3-DXd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patritumab Deruxtecan (Up-Titration)</intervention_name>
    <description>Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Study Group 2: Patritumab deruxtecan Up-Titration</arm_group_label>
    <other_name>U3-1402</other_name>
    <other_name>HER3-DXd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must meet all of the following criteria to be eligible for inclusion in this&#xD;
        study.&#xD;
&#xD;
          -  Sign and date the tissue informed consent form (ICF) and the main ICF, prior to the&#xD;
             start of any study-specific qualification procedures.&#xD;
&#xD;
          -  Male or female participants aged ≥18 years (follow local regulatory requirements if&#xD;
             the legal age of consent for study participation is &gt;18 years old).&#xD;
&#xD;
          -  Histologically or cytologically documented locally advanced or metastatic NSCLC not&#xD;
             amenable to curative surgery or radiation.&#xD;
&#xD;
          -  Documentation of radiological disease progression while on/after receiving most recent&#xD;
             treatment regimen for locally advanced or metastatic disease. Participants must have&#xD;
             received both of the following:&#xD;
&#xD;
               -  Prior treatment with osimertinib. Participants receiving an EGFR TKI at the time&#xD;
                  of signing informed consent should continue to take the EGFR TKI until 5 days&#xD;
                  prior to Cycle 1 Day 1. Participants in South Korea known to harbor a clinically&#xD;
                  actionable genomic alteration in addition to EGFR mutation (e.g., anaplastic&#xD;
                  lymphoma kinase [ALK] or ROS1 protocol oncogene 1 [ROS1] fusion) for which&#xD;
                  treatment is available must have also received prior treatment with at least 1&#xD;
                  approved genotype-directed therapy, unless unable (i.e., if contraindicated). No&#xD;
                  new testing for these genomic alterations (e.g., ALK or ROS1 fusion) is required&#xD;
                  for Screening.&#xD;
&#xD;
               -  Systemic therapy with at least 1 platinum-based chemotherapy regimen.&#xD;
&#xD;
          -  Documentation of an EGFR-activating mutation detected from tumor tissue or blood&#xD;
             sample: exon 19 deletion or L858R.&#xD;
&#xD;
          -  At least 1 measurable lesion confirmed by BICR as per RECIST v1.1&#xD;
&#xD;
          -  Consented and willing to provide required tumor tissue of sufficient quantity and of&#xD;
             adequate tumor tissue content. Required tumor tissue can be provided as either:&#xD;
&#xD;
               -  Pretreatment tumor biopsy from at least 1 lesion not previously irradiated and&#xD;
                  amenable to core biopsy OR&#xD;
&#xD;
               -  Archival tumor tissue collected from a biopsy performed within 3 months prior to&#xD;
                  signing of the tissue consent and since progression while on or after treatment&#xD;
                  with the most recent cancer therapy regimen.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Standard of 0 or 1 at Screening.&#xD;
&#xD;
          -  Has adequate bone marrow reserve and organ function based on local laboratory data&#xD;
             within 14 days prior to Cycle 1 Day 1:&#xD;
&#xD;
               -  Platelet count : ≥100,000/mm^3 or ≥100 × 10^9/L (platelet transfusions are not&#xD;
                  allowed up to 14 days prior to Cycle 1 Day 1 to meet eligibility)&#xD;
&#xD;
               -  Hemoglobin: ≥9.0 g/dL (transfusion and/or growth factor support is allowed)&#xD;
&#xD;
               -  Absolute neutrophil count: ≥1500/mm^3 or ≥1.5 × 10^9/L&#xD;
&#xD;
               -  Serum creatinine (SCr) or creatinine clearance (CrCl): SCr ≤1.5 × upper limit of&#xD;
                  normal (ULN), OR CrCl ≥30 mL/min as calculated using the Cockcroft-Gault equation&#xD;
                  or measured CrCl&#xD;
&#xD;
               -  Aspartate aminotransferase/alanine aminotransferase: ≤3 × ULN (if liver&#xD;
                  metastases are present, ≤5 × ULN)&#xD;
&#xD;
               -  Total bilirubin: ≤1.5 × ULN if no liver metastases (&lt;3 × ULN in the presence of&#xD;
                  documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver&#xD;
                  metastases)&#xD;
&#xD;
               -  Serum albumin: ≥2.5 g/dL&#xD;
&#xD;
               -  Prothrombin time (PT) or PT-International normalized ratio (INR) and activated&#xD;
                  partial thromboplastin time (aPTT)/PTT: ≤1.5 × ULN, except for subjects on&#xD;
                  coumarin-derivative anticoagulants or other similar anticoagulant therapy, who&#xD;
                  must have PT-INR within therapeutic range as deemed appropriate by the&#xD;
                  Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants meeting any exclusion criteria for this study will be excluded from this&#xD;
        study.&#xD;
&#xD;
          -  Any previous histologic or cytologic evidence of small cell OR combined small&#xD;
             cell/non-small cell disease in the archival tumor tissue or pretreatment tumor biopsy.&#xD;
&#xD;
          -  Any history of interstitial lung disease (including pulmonary fibrosis or radiation&#xD;
             pneumonitis), has current interstitial lung disease (ILD), or is suspected to have&#xD;
             such disease by imaging during screening.&#xD;
&#xD;
          -  Clinically severe respiratory compromise (based on Investigator's assessment)&#xD;
             resulting from intercurrent pulmonary illnesses including, but not limited to:&#xD;
&#xD;
               -  Any underlying pulmonary disorder (eg, pulmonary emboli within 3 months prior to&#xD;
                  the study enrollment, severe asthma, severe chronic obstructive pulmonary disease&#xD;
                  [COPD]), restrictive lung disease, pleural effusion);&#xD;
&#xD;
               -  Any autoimmune, connective tissue or inflammatory disorders with pulmonary&#xD;
                  involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis); OR prior&#xD;
                  complete pneumonectomy.&#xD;
&#xD;
          -  Is receiving chronic systemic corticosteroids dosed at &gt;10 mg prednisone or equivalent&#xD;
             anti-inflammatory or any form of immunosuppressive therapy prior to enrollment.&#xD;
             Participants who require use of bronchodilators, inhaled or topical steroids, or local&#xD;
             steroid injections may be included in the study.&#xD;
&#xD;
          -  Evidence of any leptomeningeal disease.&#xD;
&#xD;
          -  Evidence of clinically active spinal cord compression or brain metastases.&#xD;
&#xD;
          -  Inadequate washout period prior to Cycle 1 Day 1, defined as:&#xD;
&#xD;
               -  Whole brain radiation therapy &lt;14 days or stereotactic brain radiation therapy &lt;7&#xD;
                  days;&#xD;
&#xD;
               -  Any cytotoxic chemotherapy, investigational agent or other anticancer drug(s)&#xD;
                  from a previous cancer treatment regimen or clinical study (other than EGFR TKI),&#xD;
                  &lt;14 days or 5 half-lives, whichever is longer;&#xD;
&#xD;
               -  Monoclonal antibodies, other than immune checkpoint inhibitors, such as&#xD;
                  bevacizumab (anti-VEGF) and cetuximab (anti-EGFR) &lt;28 days;&#xD;
&#xD;
               -  Immune checkpoint inhibitor therapy &lt;21 days;&#xD;
&#xD;
               -  Major surgery (excluding placement of vascular access) &lt;28 days;&#xD;
&#xD;
               -  Radiotherapy treatment to more than 30% of the bone marrow or with a wide field&#xD;
                  of radiation &lt;28 days or palliative radiation therapy &lt;14 days; or&#xD;
&#xD;
               -  Chloroquine or hydroxychloroquine &lt;14 days.&#xD;
&#xD;
          -  Prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody&#xD;
             or single-agent topoisomerase I inhibitor.&#xD;
&#xD;
          -  Prior treatment with an antibody drug conjugate (ADC) that consists of any&#xD;
             topoisomerase I inhibitor&#xD;
&#xD;
          -  Has unresolved toxicities from previous anticancer therapy, defined as toxicities&#xD;
             (other than alopecia) not yet resolved to National Cancer Institute Common Terminology&#xD;
             Criteria for Adverse Events (NCI-CTCAE) v5.0, Grade ≤1 or baseline. Participants with&#xD;
             chronic Grade 2 toxicities may be eligible at the discretion of the Investigator after&#xD;
             consultation with the Sponsor Medical Monitor or designee.&#xD;
&#xD;
          -  Has history of other active malignancy within 3 years prior to enrollment, except:&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer;&#xD;
&#xD;
               -  Superficial bladder tumors (Ta, Tis, T1);&#xD;
&#xD;
               -  Adequately treated intraepithelial carcinoma of the cervix uteri;&#xD;
&#xD;
               -  Low risk non-metastatic prostate cancer (with Gleason score &lt;7, and following&#xD;
                  local treatment or ongoing active surveillance);&#xD;
&#xD;
               -  Any other curatively treated in situ disease.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1&#xD;
&#xD;
          -  Active hepatitis B and/or hepatitis C infection, such as those with serologic evidence&#xD;
             of viral infection within 28 days of Cycle 1 Day 1.&#xD;
&#xD;
          -  Participant with any human immunodeficiency virus (HIV) infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>(US sites only) Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>908-992-6400</phone>
    <email>CTRinfo@dsi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>(Asia sites only) Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>+81-3-6225-1111(M-F 9-5 JST)</phone>
    <email>dsclinicaltrial@daiichisankyo.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moores Cancer Center at the UC San Diego Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California at Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver - Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist-North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists-Panhandle</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists-East</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Marlene and Stewart Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH) - Hematology/Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center, Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute/Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon HCA Midwest Healthcare - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Main Campus</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center - Emily Couric Clinical Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialist, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hosital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Public Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St John of God Subiaco Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Uni Hospital OOD</name>
      <address>
        <city>Panagyurishte</city>
        <zip>4500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complex Oncological Center - Russe</name>
      <address>
        <city>Russe</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Serdika</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Chang chun</city>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes - Thoracic Oncology</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Morvan CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Koeln gGmbH Lungenklinik Merheim</name>
      <address>
        <city>KÃ¶ln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaet zu Koeln - Uniklinik Koeln</name>
      <address>
        <city>Koeln</city>
        <state>North Rhine-Westphal</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LungenClinic Grosshansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Cancer Center</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LungenClinic Grosshansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaet zu Koeln - Uniklinik Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Koeln gGmbH Lungenklinik Merheim</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Scientifico Romagnolo per lo Studio e La Cura Dei Tumori ISRT</name>
      <address>
        <city>Meldola</city>
        <state>Province Of Forlì-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>Province Of Parma</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Turin</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Scientifico Romagnolo per lo Studio e La Cura Dei Tumori ISRT</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Cancer Center</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-0882</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <state>Chuo-ku</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba</city>
        <state>Kashiwa-shi</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Ariake</city>
        <state>Koto</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Ōsaka-sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1347</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo</city>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Marys Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Cancer Institute National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore NCCS</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OncoCare Cancer Centre- Gleneagles Medical Centre</name>
      <address>
        <city>Singapore</city>
        <zip>258499</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catalan Institute of Badalona Hospital Germans Trias i Pujol ICO</name>
      <address>
        <city>Badalona</city>
        <state>Cataluã'a</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro de Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Bleza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital CGMH - Kaohsiung Branch</name>
      <address>
        <city>Niaosong</city>
        <state>Gao Xiong Shi</state>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <state>Tai Nan Shi</state>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital CGMH - Kaohsiung Branch</name>
      <address>
        <city>Niaosong</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>420</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital NTUH</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer Metastatic</keyword>
  <keyword>Non-Small Cell Lung Cancer with Mutation in Epidermal Growth Factor Receptor</keyword>
  <keyword>Epidermal growth factor receptor</keyword>
  <keyword>HER3-DXd</keyword>
  <keyword>Patritumab Deruxtecan</keyword>
  <keyword>U3-1402</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Patritumab deruxtecan</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

